Inclusion Criteria:

1. All patients with a diagnosis of complex atypical hyperplasia or endometrial biopsy within three months of study enrollment OR patients with a diagnosis of grade 1 endometrioid endometrial carcinoma on endometrial biopsy within three months of study enrollment in the presence of one or more of the following: 1)desire for future fertility 2)morbid obesity (body mass index > 40) 3)multiple co-morbidities (ASA Class 3 or 4)
2. No prior treatment for diagnoses in inclusion criteria 1.
3. Women of any racial or ethnic group.
4. Ability to comply with endometrial biopsies every 3 months.
5. Willing and able to sign informed consent.
6. Age greater than 18 years.

Exclusion Criteria:

1. Diagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion criteria 1.
2. Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen.
3. Evidence of extrauterine spread of disease on imaging or during surgical evaluation.
4. Congenital or acquired uterine anomaly which distorts the uterine cavity.
5. Acute pelvic inflammatory disease.
6. Acute liver disease or previously diagnosed liver tumor (benign or malignant).
7. Conditions associated with increased susceptibility to infections with microorganisms. Such conditions include, but are not limited to, AIDS, leukemia and IV drug abuse.
8. Genital actinomycosis.
9. Current carcinoma of the breast.
10. Current pregnancy.
11. Breastfeeding mothers.